Skip to main content
Feedback to SSRN
Feedback
(required)
Email
(required)
Submit
Alexandre Fugère
Immune Biosolutions Inc
Learn more about SSRN Profiles
SCHOLARLY PAPERS
1
DOWNLOADS
182
TOTAL CITATIONS
0
Feedback
Scholarly Papers (1)
Sort by:
Paper Title, A-Z
Paper Title, Z-A
Author Name, A-Z
Author Name, Z-A
Date Posted, Ascending
Date Posted, Descending
Downloads, Ascending
Downloads, Descending
Citations, Ascending
Citations, Descending
Actions:
Email selected abstracts
View:
Selected
Original List
All Versions
Hide All Versions
All Abstracts
Hide All Abstracts
(Rank)
1.
Safety and Efficacy of Inhaled IBIO123 for Severe COVID-19: A Randomised, Double-Blind, Dose-Ascending, Placebo-Controlled, Phase 1/2 Trial
Number of pages: 35
Posted: 06 Oct 2023
Sébastien M. Labbé
,
Bruno Maranda
,
Magali Lurquin
,
Pascal Brabant
, Alexandre Fugère,
Jean-François Larrivée
,
Djordje Grbic
,
Annie Leroux
,
Frédéric Leduc
,
Andres Finzi
,
Simon Gaudreau
,
Larry D. Mey
and
IBIO-INH-002 Investigators
Immune Biosolutions Inc, Immune Biosolutions Inc, Immune Biosolutions Inc, Immune Biosolutions Inc, Immune Biosolutions Inc, Immune Biosolutions Inc, Immune Biosolutions Inc, Immune Biosolutions Inc, Immune Biosolutions Inc, Centre de Recherche du CHUM, Immune Biosolutions Inc, Ryexo Clinical Research and Independent
Downloads
182
(422,345)
View PDF
Download
Abstract:
COVID-19, monoclonal antibody, inhalation, therapy
Feedback
